Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

Table 4

Comparative clinical studies describing outcomes for patients receiving intravenous fosfomycin in combination with a second antimicrobial agent.

Trial design (reference); Infection type ()	Treatment regimens and outcomes	Pathogens
Open label nonrandomized [55]; Septicemia (32), osteoarthritis (1), meningitis (1), and pulmonary infection (1)	Group 1: 17 patients fosfomycin (237.1 mg/kg daily IV)/penicillin; Cure: 16/17 (94.1%); Group 2: 18 patients gentamicin/penicillin; Cure: 14/18 (77.7%)	MSSA
Prospective randomized [56]; Ventilator-associated pneumonia (22) and pneumonia (10)	Group 1: 17 patients fosfomycin (12 g daily IV)/ampicillin; Cure: 10/17 (58.8%); improvement: 6/17 (35.2%); Group 2: 15 patients gentamicin/ampicillin; Cure: 7/15 (46.6%); improvement: 5/15 (33.3%)	E. coli, coagulase-positive staphylococci, P. aeruginosa, and Klebsiella